Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
- Monday, August 3, 2020, 7:08
- Finance
- Add a comment
TITUSVILLE, N.J., Aug. 3, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an…
About the Author
adminasapcorp has written 39302 stories on this site.